Biotinylated Recombinant Human PD-L2-Fc Chimera (carrier-free)

Pricing & Availability
Regulatory Status
Other Names
CD273, Programmed cell death 1 ligand 2 (PD-L2), B7 dendritic cellmolecule (B7-DC), Butyrophilin B7-DC, PDCD1 Ligand 2
Ave. Rating
Submit a Review
Product Citations
When recombinant human PD-1 is immobilized at 1 µg/mL, biotinylated recombinant human PD-L2 binds in a dose-dependent manner with ED50 range of 1 – 6 ng/mL. HRP Avidin (Cat. No. 405103) was used to detect the binding.
  • Biotin_Human_PD-L2-Fc-Chimera_1_CF
    When recombinant human PD-1 is immobilized at 1 µg/mL, biotinylated recombinant human PD-L2 binds in a dose-dependent manner with ED50 range of 1 – 6 ng/mL. HRP Avidin (Cat. No. 405103) was used to detect the binding.
  • Biotin_Human_PD-L2-Fc-Chimera_2_CF
    Stability Testing for Biotinylated Recombinant Human PD-L2. Biotinylated Recombinant Human PD-L2 was aliquoted in PBS, 5% Glycerol at 0.2 mg/mL. One aliquot was frozen and thawed four times (4x Freeze/Thaw), and compared to a control kept at 4°C (Control). The samples were tested in a binding assay with recombinant human PD-1. The ED50 for this effect is 1 – 6 ng/mL.
Cat # Size Price Save
565604 25 µg ¥68,660
565606 100 µg ¥174,130

PD-L2 is a type I transmembrane protein of 273 amino acids, and it is a member of the B7 family. Human PD-L2 has 70% amino acid identity to its mouse orthologue. PD-L2 is the second ligand for PD-1, and its binding to PD-1 leads to the inhibition of T cell receptor–mediated lymphocyte proliferation and cytokine secretion. PD-L2/PD-1 interaction suppresses immune responses against autoantigens and tumors and plays an important role in the maintenance of peripheral immune tolerance. Antibody blocking of PD-L2 on dendritic cells results in enhanced T cell proliferation and cytokine production. Interaction of PD-1 by PD-L1-Ig or PD-L2-Ig fusion protein has an inhibitory effect on proliferation and cytokine production during anti-CD3-mediated stimulation. PD-L2 is expressed in biopsies from human asthmatics and lungs of aeroallergen-treated mice and its expression correlates with the asthma severity. In vivo blockade of PD-L2 reduces the severity of allergen-driven airway hyperresponsiveness (AHR).  Blockage of PD-L2 induces the IL-12 production by DC; IL-12 may limit the severity of allergen-induced AHR antagonizing IL-13. In addition, blockade of PD-1 does not have effect on AHR; therefore, PD-L2 controls asthma severity in a PD-1 independent manner. PD-L2 binds to a second receptor, RGMb (repulsive guidance molecule b) which is expressed in lung interstitial macrophages and alveolar epithelial cells and is a co-receptor for bone morphogenetic proteins BMP2/4. Blockade of the RGMb/PD-L2 interaction significantly impaired the development of respiratory tolerance since the initial T cell expansion is inhibited.

Product Details
Technical data sheet

Product Details

Human PD-L2, amino acid (Leu20-Pro219) (Accession # Q9BQ51.2), with a linker (SRIEG), a C-terminal human IgG1 (Pro100-Lys330) and an Avi-tag, was expressed in CHO cells. Human PD-L2-Avi tag was site-specifically biotinylated by enzyme BirA.
Molecular Mass
The 453 amino acid recombinant protein has a predicted molecular mass of approximately 50.97 kD. The DTT-reduced and non-reduced protein migrate at approximately 65 – 80 kD and 140 – 160 kD by SDS-PAGE, respectively. The predicted N-terminal amino acid is Leu.
> 95%, as determined by Coomassie-stained SDS-PAGE
0.22 µm filtered protein solution is in PBS, 5% Glycerol
Endotoxin Level
Less than 0.1 EU per µg cytokine as determined by the LAL method
25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
When recombinant human PD-1 (Cat. No. 785106) is immobilized at 1 µg/mL, biotinylated recombinant human PD-L2 binds in a dose-dependent manner with ED50 range of 1 – 6 ng/mL. HRP-Avidin (Cat. No. 405103) was used to detect the binding.


Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at

Antigen Details


Immature dendritic cells, mature dendritic cells, subset of macrophages, placental endothelium, and medullary thymic epithelial cells

Inhibits T cell mediated proliferation and cytokine production by CD4+ T cells, and regulates T cell responses. PD-L2 expression is up-regulated on antigen-presenting cells by IFNγ.
Fibroblast growth factor receptors (FGFRs)
PD-1 (CD279), RGMb
Biotinylated recombinant human PD-L2 binds to immobilized recombinant human PD-1 in a dose-dependent manner.
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules, Immune Checkpoint Receptors, Soluble Receptors
Antigen References
  1. Latchman Y, et al. 2001. Nat Immunol. 2:261-8
  2. Brown JA, et al. 2003. J Immunol. 170:1257-66.
  3. Youngnak P, et al. 2003. Biochem Biophys Res Commun. 307:672-7.
  4. Singh AK, et al. 2011. Allergy. 66:155-62.
  5. Lewkowich IP, et al. 2013. Mucosal Immunol. 6:728-39.
  6. Xiao Y, et al. 2014. J Exp Med. 211:943-59.
  7. Bardhan K, et al. 2016. Front Immunol. 7:550.
Gene ID
80380 View all products for this Gene ID
View information about PD-L2 on

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 08/18/2023

For Research Use Only. Not for diagnostic or therapeutic use.


This product is supplied subject to the terms and conditions, including the limited license, located at ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.


BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.


8999 BioLegend Way, San Diego, CA 92121
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587


Login / Register
Remember me
Forgot your password? Reset password?
Create an Account